IP Library › Granted Patent US 12,370,229
Granted Patent B2
US 12,370,229 · App. 17/713,975 · Granted Jul 29, 2025

Methods of treating bladder cancer

Inventor: Arthur Kuan (Newport Coast, CA)
Assignee: CG ONCOLOGY, INC.
A61K35/761A61K9/0034A61P35/00A61K35/76A61K35/768C12N7/00C12N2710/10032C12N2710/10332
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,229
App. No.
17/713,975
Granted
Jul 29, 2025
Kind
B2
Abstract

The present invention provides methods for treating an individual having bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating bladder cancer.

Claims (29)

1. A method of treating bladder cancer or preserving bladder in an individual with bladder cancer, comprising intravesically administering to the individual an effective amount of an oncolytic virus once per week for six weeks during an induction phase, and subsequently intravesically administering an effective amount of the oncolytic virus once per week for three weeks every three or six months during a maintenance phase, wherein the start of the induction phase and the start of the maintenance phase are separated by about three months or about six months, wherein the oncolytic virus is an adenovirus serotype 5, wherein the endogenous Ela promoter of the native adenovirus is replaced by the human E2F-1 promoter, and the endogenous E3 19kD coding region of the native adenovirus is replaced by a nucleic acid encoding human GM-CSF, and wherein the oncolytic virus is administered at a dose of about 1×10 8 to about 1×10 14 viral particles.

2. The method of claim 1 , wherein the start of the induction phase and the start of the maintenance phase are separated by about 3 months.

3. The method of claim 1 , wherein the start of the induction phase and the start of the maintenance phase are separated by about 6 months.

4. The method of claim 1 , wherein the induction phase comprises administering to the individual an effective amount of the oncolytic virus once per week for six weeks on month zero and month three of a treatment regimen.

5. The method of claim 1 , wherein the individual has carcinoma in situ.

6. The method of claim 5 , wherein the individual does not have a concurrent papillary carcinoma of Ta or T1 stage.

7. The method of claim 1 , wherein the individual has Ta or T1 stage bladder cancer.

8. The method of claim 1 , wherein the individual is unresponsive to BCG treatment.

9. The method of claim 1 , wherein the individual has disease reoccurrence subsequent to BCG treatment.

10. The method of claim 1 , wherein the individual has failed BCG treatment within about 6 months.

11. The method of claim 1 , wherein the individual has not received a cystectomy.

12. The method of claim 11 , wherein the individual has refused or is ineligible for a cystectomy.

13. The method of claim 1 , wherein the oncolytic virus is CG0070.

14. The method of claim 1 , further comprising intravesically administering to the individual a transduction enhancing agent prior to the administration of the oncolytic virus.

15. The method of claim 1 , wherein the oncolytic virus is administered as a single therapeutic agent.

16. The method of claim 7 , wherein the individual does not have carcinoma in situ.

17. The method of claim 7 , wherein the Ta or T1 stage bladder cancer is high grade Ta or T1 stage bladder cancer.

18. The method of claim 1 , wherein the individual has recurrent high grade Ta or T1 stage bladder cancer after no more than 6 months of completion of at least 7 intravesical instillations of BCG, wherein the individual does not have carcinoma in situ.

19. The method of claim 1 , wherein the individual has persistent or recurrent carcinoma in situ after no more than 12 months of completion of at least 7 intravesical instillations of BCG.

20. The method of claim 1 , wherein the individual is administered the oncolytic virus once per week for six weeks on month zero during the induction phase and is reevaluated at month three.

21. The method of claim 20 , wherein the individual begins the maintenance phase at month three.

22. The method of claim 21 , wherein the maintenance phase comprises administering the oncolytic virus once per week for three weeks every three months for nine months and subsequently administering the oncolytic virus once per week for three weeks every six months.

23. The method of claim 20 , wherein the individual receives a second induction dose of oncolytic virus once per week for six weeks at month three.

24. The method of claim 23 , wherein the maintenance phase comprises administering the oncolytic virus once per week for three weeks every three months for six months and subsequently administering the oncolytic virus once per week for three weeks every six months.

25. The method of claim 1 , wherein the maintenance phase comprises:

(i) administering the oncolytic virus once per week for three weeks every three months for six to nine months, and subsequently

(ii) administering the oncolytic virus once per week for three weeks every six months.

26. The method of claim 1 , wherein the individual has non-muscle invasive bladder cancer.

27. The method of claim 14 , wherein the transduction enhancing agent is N-Dodecyl-β-D-maltoside (DDM).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2022
From: KUAN, ARTHUR
To: CG ONCOLOGY, INC.
Reel/Frame 059559/0446 →
Continuity (4)
Continuation 16605066
Provisional Application 62500729 · May 3, 2017
Provisional Application 62485805 · Apr 14, 2017
Related Publication 20220296658A1 · Sep 22, 2022
References Cited (168)
US 4590071A · Scannon · 1986 [cited by applicant]
US 6432700B1 · Henderson et al. · 2002 [cited by applicant]
US 6495130B1 · Henderson et al. · 2002 [cited by applicant]
US 6682736B1 · Hanson · 2004 [cited by applicant]
US 6692736B2 · Yu et al. · 2004 [cited by applicant]
US 6900049B2 · Yu et al. · 2005 [cited by applicant]
US 6984720B1 · Korman · 2006 [cited by applicant]
US 6991935B2 · Henderson et al. · 2006 [cited by applicant]
US 7001764B2 · Little et al. · 2006 [cited by applicant]
US 7109003B2 · Hanson · 2006 [cited by applicant]
US 7132281B2 · Hanson · 2006 [cited by applicant]
US 7229628B1 · Allison · 2007 [cited by applicant]
US 7267815B2 · Ramesh et al. · 2007 [cited by applicant]
US 7411057B2 · Hanson · 2008 [cited by applicant]
US 7452535B2 · Davis · 2008 [cited by applicant]
US 7459154B2 · Ramesh et al. · 2008 [cited by applicant]
US 7473418B2 · Yu et al. · 2009 [cited by applicant]
US 7575919B2 · Yu et al. · 2009 [cited by applicant]
US 7807797B2 · Hanson · 2010 [cited by applicant]
US 7824679B2 · Hanson · 2010 [cited by applicant]
US 7858083B2 · Yu et al. · 2010 [cited by applicant]
US 7928074B2 · Khare · 2011 [cited by applicant]
US RE42373E · Yu et al. · 2011 [cited by applicant]
US 7959925B2 · Weinberg · 2011 [cited by applicant]
US 7968333B2 · Yu et al. · 2011 [cited by applicant]
US 8017114B2 · Korman · 2011 [cited by applicant]
US 8088905B2 · Collins · 2012 [cited by applicant]
US 8142778B2 · Davis · 2012 [cited by applicant]
US 8143379B2 · Hanson · 2012 [cited by applicant]
US 11338003B2 · Kuan · 2022 [cited by applicant]
US 20030039633A1 · Yu · 2003 [cited by applicant]
US 20040197312A1 · Moskalenko · 2004 [cited by applicant]
US 20050186178A1 · Ennist · 2005 [cited by applicant]
US 20050282280A1 · Ennist · 2005 [cited by applicant]
US 20060062764A1 · Police · 2006 [cited by applicant]
US 20100040614A1 · Ahmed · 2010 [cited by applicant]
US 20100150946A1 · Jooss · 2010 [cited by applicant]
US 20100166799A1 · Hemminki · 2010 [cited by applicant]
US 20100247440A1 · Morton · 2010 [cited by applicant]
US 20110044953A1 · Allison · 2011 [cited by applicant]
US 20130084263A1 · Podhajcer et al. · 2013 [cited by applicant]
US 20150190505A1 · Yeung · 2015 [cited by applicant]
US 20160108123A1 · Freeman · 2016 [cited by applicant]
US 20160289645A1 · Tufaro · 2016 [cited by applicant]
US 20180318365A1 · Yeung · 2018 [cited by applicant]
US 20190070233A1 · Yeung · 2019 [cited by applicant]
US 20200171151A1 · Yeung · 2020 [cited by applicant]
US 20210085734A1 · Kuan · 2021 [cited by applicant]
US 20220125864A1 · Yeung et al. · 2022 [cited by applicant]
US 20220331384A1 · Kuan · 2022 [cited by applicant]
US 20230052537A1 · Yeung et al. · 2023 [cited by applicant]
AU 2003252891A1 · 2003 [cited by applicant]
EP 2604110A2 · 2013 [cited by applicant]
EP 2879498A2 · 2015 [cited by applicant]
JP 2006525995A · 2006 [cited by applicant]
JP 2008510493A · 2008 [cited by applicant]
JP 2010514791A · 2010 [cited by applicant]
SG 1020180156P · 2018 [cited by applicant]
TW 200607859A · 2006 [cited by applicant]
WO 199839464A2 · 1998 [cited by applicant]
WO 199839464A3 · 1998 [cited by applicant]
WO 200015820A1 · 2000 [cited by applicant]
WO 200039319A2 · 2000 [cited by applicant]
WO 200039319A3 · 2000 [cited by applicant]
WO 200173093A2 · 2001 [cited by applicant]
WO 200173093A3 · 2001 [cited by applicant]
WO 200200730A2 · 2002 [cited by applicant]
WO 200200730A3 · 2002 [cited by applicant]
WO 2004060303A2 · 2004 [cited by applicant]
WO 2004060303A3 · 2004 [cited by applicant]
WO 2005030261A1 · 2005 [cited by applicant]
WO 2005103272A2 · 2005 [cited by applicant]
WO 2005103272A3 · 2005 [cited by applicant]
WO 2007052029A1 · 2007 [cited by applicant]
WO 2007123737A2 · 2007 [cited by applicant]
WO 2007126805A2 · 2007 [cited by applicant]
WO 2010072900A1 · 2010 [cited by applicant]
WO 2012038606A1 · 2012 [cited by applicant]
WO 2013112942A1 · 2013 [cited by applicant]
WO 2013132044A1 · 2013 [cited by applicant]
WO 2014022138A2 · 2014 [cited by applicant]
WO 2014022138A3 · 2014 [cited by applicant]
WO 2014170389A1 · 2014 [cited by applicant]
WO 2016009017A1 · 2016 [cited by applicant]
WO 2016145354A1 · 2016 [cited by applicant]
WO 2017070110A1 · 2017 [cited by applicant]
WO 2017156349A1 · 2017 [cited by applicant]
Burke et al., The Journal of Urology, Dec. 2012, 188:2391-2397. (Year: 2012). [cited by examiner]
Packiam et al., The Journal of Urology, May 6, 2016, 195(4S):e142. (Year: 2016). [cited by examiner]
Clinical Trial NCT01438112 (2011). (Year: 2011). [cited by examiner]
Ramesh et al., Clin Cancer Res, 2006, 12(1):305-313. (Year: 2006). [cited by examiner]
Anonymous (Jun. 19, 2014). “Immune CheckPoint-Modulating T-Cells Regulation,” Epoch Times, 7 pages with English Translation. [cited by applicant]
Anonymous: (Apr. 12, 2021). “History of Changes for Study: NCT01438112: Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND)—NCT01438112”, ClinicalTrials.gov, Retrieved from the Interne… [cited by applicant]
Anonymous: (Sep. 21, 2011). “Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND)—NCT01438112,” ClinicalTrials.gov, Sep. 21, 2011 (Sep. 21, 2011), XP055557337, Retrieved from the Intern… [cited by applicant]
Ao, J.-H. et al. (2013). “Optimal Management of Metastatic Melanoma,” J. Pract. Dermatol. 6(4):219-223. English Abstract Only. [cited by applicant]
Bassi, P. et al. (May 1999). “Prognostic Factors Of Outcome After Radical Cystectomy For Bladder Cancer: A Retrospective Study Of A Homogeneous Patient Cohort,” Urol. 161(5):1494-1497. [cited by applicant]
Boehm, B.E. et al. (2015). “Novel Therapeutic Approaches for Recurrent Nonmuscle Invasive Bladder Cancer,” Urol. Clin. N. Am. 42:159-168. [cited by applicant]
Bramante, S. (Oct. 2, 2015). “Oncolytic Adenovirus Coding For Gm-Csf In Treatment Of Cancer,” Faculty Of Medicine Of The University Of Helsinki Academic Dissertation, pp. 1-101. [cited by applicant]
Bridle, B.W. et al. (Apr.-Jun. 2010, epub. Mar. 11, 2010). “Combining Oncolytic Virotherapy and Tumour Vaccination,” Cytokine & Growth Factor Reviews 21(2-3):143-148. [cited by applicant]
Bristol, J.A. et al. (Jun. 2003). “In Vitro and In Vivo Activities of an Oncolytic Adenoviral Designed to Express GM-CSF,” Molecular Therapy 7(6):755-784. [cited by applicant]
Burke, J.M. et al. (Dec. 2012, e-pub. Oct. 22, 2012). “A First in Human Phase I Study ofCG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer,” The Journal Of Urology 1… [cited by applicant]
Carthon et al. (2010, e-pub. May 11, 2010). “Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial,” Clin. Cancer Res. 16(10):2861-2871. [cited by applicant]
clinicaltrials.gov (Sep. 2011). “Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND),” Clinica1Trials.gov Identifier: NCT01438112, retrieved from internet URL:https://clinicaltrials.go… [cited by applicant]
ClinicalTrials.gov. (Feb. 19, 2019). “Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure—Full Text View—ClinicalTrials.gov,” ClinicalTrials.gov Identifier: NCT02365818, Retrieve… [cited by applicant]
Dias, J.D. et al. (2012, e-pub. Nov. 10, 2011). “Target Cancer Immunotherapy With Oncolytic Adenovirus Coding For a Fully Human Monoclonal Antibody Specific For CTLA-4,” Gene Therapy 19:988-998. [cited by applicant]
Dong, Y.B. et al. (Mar. 15, 2002). “Adenovirus-Mediated E2F-1 Gene Transfer Sensitizes Melanoma Cells to Apoptosis Induced by Topoisomerase II Inhibitors,” Cancer Research 62(6):1776-1783. [cited by applicant]
Dranoff, G. et al. (Apr. 1993). “Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulationg Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity,”… [cited by applicant]
European Extended Search Report, dated Jun. 19, 2019, for European Patent Application No. 16858069.4, 7 pages. [cited by applicant]
European Extended Search Report, dated Sep. 17, 2019, for European Patent Application No. 17764159.4, 12 pages. [cited by applicant]
Extended European Search Report, dated Feb. 19, 2021, for European Patent Application No. 18784592.0, 8 pages. [cited by applicant]
Fonseca, C. et al. (Feb. 19, 2009, epub. Nov. 13, 2008). “Protein Disulfide Isomerases are Antibody Targets During Immune-Mediated Tumor Destruction,” Blood 113(8):1681-1688. [cited by applicant]
Friedlander, T W et al. (May 20, 2012). “Activity of Intravesical CG0070 In Rb-Inactive Superficial Bladder Cancer After BCG Failure: Updated Results of a Phase I/II Trial,” Journal of Clinical Oncology 30(15): Abstract… [cited by applicant]
Fukuhara, H. et al. (Oct. 2016, e-pub. Sep. 9, 2016). “Oncolytic virus therapy: A new era of cancer treatment at dawn,” Cancer Science 107(10):1373-1379. [cited by applicant]
GenBank Accession No. AF516106 (Jun. 5, 2002). “ [cited by applicant]
GenBank Accession No. AH006643.2 (Jun. 10, 2016). “ [cited by applicant]
Hemminkio, O. et al. (Feb. 24, 2015). “Immunological Data from Cancer Patients Treated with Ad5/3-E2F-Δ24-GMCSF Suggests Utility for Tumor Immunotherapy,” Oncotarget 6(6):4467-4481. [cited by applicant]
Hsu, S. et al. (2015). “Cold Genesys Annouces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a NewAdjuvant Immunotherapy for Muscle Invasive Bladder Cancer,” http:… [cited by applicant]
Hu, Z.-B. et al. (Apr. 2008). “Antitumor Effect of Recombinant Oncolytic Adenovirus Ad-CD80-TPE-GM in Hep2 Xenograft Tumor Model,” Chin. Med. Biotechnol. 3(2):116-120, English Abstract on p. 120. [cited by applicant]
International Preliminary Report On Patentability for PCT/US2013/51535 dated Oct. 30, 2014, filed on Jul. 22, 2013, 10 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2017/021694 issued Sep. 11, 2018, on May 23, 2017, filed on Mar. 9, 2017, 5 pages. [cited by applicant]
International Preliminary Report on Patentability PCT/US2016/057526, issued Apr. 24, 2018, filed on Oct. 18, 2016, 6 pages. [cited by applicant]
International Preliminary Report on Patentability, issued Oct. 15, 2019, for PCT Application No. PCT/US2018/02749, filed Apr. 13, 2018, 10 pages. [cited by applicant]
International Search Report And Written Opinion for PCT/US2016/057526, mailed on Dec. 30, 2016, filed on Oct. 18, 2016, 39 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Jun. 22, 2018, for PCT Application No. PCT/US2018/02749, filed Apr. 13, 2018, 16 pages. [cited by applicant]
International Search Report for PCT/US2013/51535 mailed on Feb. 4, 2014, filed on Jul. 22, 2013, 5 pages. [cited by applicant]
International Search Report for PCT/US2017/021694 mailed on May 23, 2017, filed on Mar. 9, 2017, 5 pages. [cited by applicant]
Ishihara, M. et al. (Aug. 8, 2014). “Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced… [cited by applicant]
Kaufman, H.L. et al. (Sep. 2015). “Oncolytic Viruses: A New Class Of Immunotherapy Drugs,” Nature Reviews. Drug Discovery 14(9):642-662. [cited by applicant]
Kikuchi, J. et al. (2007, e-pub. Jun. 28, 2007). “E2F-6 Suppresses Growth-Associated Apoptosis Of Human Hematopoietic Progenitor Cells by Counteracting Proapoptotic Activity of E2F-1,” Stem Cells 25:2439-1447. [cited by applicant]
Kwek, S.S. et al. (Apr. 2012). “Unmasking the Immune Recognition of Prostate Cancer with CTLA4 Blockage,” Nature Reviews 12:289-297. [cited by applicant]
Lamm, D. et al. (2006). A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma (TCC) of the Bladder After Bacillus Calmette-Guerin (BCG) Failure, retrieved from http://media.c… [cited by applicant]
Liu, B. et al. (Feb. 28, 2003). “ICP34.5 Deleted Herpes Simplex Virus With Enhanced Oncolytic, Immune Stimulating, and Anti-Tumour Properties,” Gene Ther. 10(4):292-303. [cited by applicant]
Mangsbo, S.M. et al. (Apr. 2010). “Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade with CpG Therapy,” J. Immunother. 33(3):225-235. [cited by applicant]
Melero, I. et al. (Sep. 2014, epub. Jul. 8, 2014). “Therapeutic Vaccines for Cancer: An Overview of Clinical Trials,” Nature Reviews Clinical Oncology 11(9):509-524. [cited by applicant]
Non-Final Office Action, mailed Oct. 26, 2021, for U.S. Appl. No. 16/605,066, filed Oct. 14, 2019, 17 pages. [cited by applicant]
Ohaegbulam, K.C. et al. (Jan. 2015). “Human Cancer Immunotherapy With Antibodies to the PD-1 and PD-L1 Pathway,” Trends in Molecular Medicine 21(1):24-33. [cited by applicant]
ONCOS102 (Previously CGTG102) (Oct. 1, 2014). for “Therapy of Advanced Cancers,” NCT01598129, https://clinicaltrials.gov/archive/NCT01598129/2014_10_01 retrieved from internet May 10, 2017, last visited Jun. 23, 2017. [cited by applicant]
Packiam, V.T. et al. (Mary 6, 2016). “MP13-19: A Phase II/III Trial Of Cg0070, An Oncolytic Adenovirus, For Bcg-Refractory Non-Muscle-Invasive Bladder Cancer (NMI BC),” Journal Of Urology, 195(Supple. 4s):e142, 1 page. [cited by applicant]
Packiam, V.T. et al. (Oct. 2018, e-pub. Jul. 26, 2017). “An Open Label, Single-Arm, Phase II Multicenter Study Of The Safety and Efficacy Of CG0070 Oncolytic Vector Regimen In Patients With BCG-Unresponsive Non-Muscle-I… [cited by applicant]
Packiam, V.T. et al. “Interim Results from A Single-Arm Multicenter Phase II Trial of CG0070, an Oncolytic Adenovirus, for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC),” retrieved from https://university.… [cited by applicant]
Rajani, K. et al. (Feb. 2016, e-pub. Aug. 27, 2015). “Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses,” Molecular Therapy 24(1):166-174. [cited by applicant]
Ramesh, N et al. (May 2005). “CG0070, A Conditionally Replicating GM-CSF Armed Oncolytic Adenovirus For The Treatment Of Bladder Cancer,” Proceedings of the American Association for Cancer Research Annual 46:1185, Abstr… [cited by applicant]
Ramesh, N. et al. (Jan. 1, 2006). “CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor—Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer,” Clin. Cancer Res. 12(1):305-313. [cited by applicant]
Savoia, P. et al. (May 2016, e-pub. Feb. 18, 2016). “Ipilimumab (Anti-Ctla-4 Mab) In The Treatment of Metastatic Melanoma: Effectiveness and Toxicity Management,” Hum. Vaccin. Immunother 12(5):1092-1101. [cited by applicant]
Senzer, N. et al. (May 2006). “A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma (TCC) of the Bladder After Bacillus Calmette-Guerin (BCG) Failure,” Molecular Therapy, 13… [cited by applicant]
Shoyaib, A.A. et al. (2020, e-pub. Dec. 2019). “Intraperitoneal Route of Drug Administration: Should It Be Used in Experimental Animal Studies?” Pharm. Res. 37:12, 17 pages. [cited by applicant]
Simmons, A.D. et al. (2008, epub. Jan. 31, 2008). “Local Secretion of Anti-CTLA-4 Enhances the Therapeutic Efficacy of a Cancer Immunotherapy with Reduced Evidence of Systemic Autoimmunity,” Cancer Immunology, Immunothe… [cited by applicant]
Sistigu, A. et al. (Jul. 2011, e-pub. May 25, 2011). “Immunomodulatory Effects Of Cyclophosphamide and Implementations For Vaccine Design,” Seminars in Immunopathology 33(4):369-383. [cited by applicant]
Sorensen, M.R. et al. (2010, epub. Aug. 2, 2010). “Adenoviral Vaccination Combined with CD40 Stimulation and CTLA-4 Blockage Can Lead to Complete Tumor Regression in a Murine Melanoma Model,” Vaccine 28:6757-6764. [cited by applicant]
Tang, L. et al. (Apr. 2015). “Progress in Drug Therapy For Small Cell Lung Cancer,” Progress in Modern Biomedicine 15(10):1963-1970. English Abstract Only. [cited by applicant]
Van Den Eertwegh, A.J.M. et al. (May 2012). “Combined Immunotherapy with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Allogeneic Prostate Cancer Cells and Ipilimumab in Patients with Metastatic Castration… [cited by applicant]
Weber, J. (2007). “Review: Anti-CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events,” The Oncologist 12(7):864-872. [cited by applicant]
Witjes, J.A. (Feb. 2014). “Bladder Carcinoma In Situ In 2003: State Of The Art,” European Urology 45(2):142-146. [cited by applicant]
Written Opinion Of The International Search Authority for PCT/US2013/51535 mailed on Feb. 4, 2014, filed on Jul. 22, 2013, 6 pages. [cited by applicant]
Written Opinion Of The International Search Authority for PCT/US2017/021694 mailed on May 23, 2017, filed on Mar. 9, 2017, 4 pages. [cited by applicant]
Zamarin, D. et al. (Dec. 2014). “Potentiation of Immunomodulatory Antibody Therapy With Oncolytic Viruses For Treatment of Cancer,” Molecular Therapy 1:14004, 10 pages. [cited by applicant]
Zhai, Z. et al. (Nov. 2012, e-pub. Jan. 5, 2012). “Antitumor Effects Of Bladder Cancer-Specific Adenovirus Carrying E1A-Androgen Receptor In Bladder Cancer,” Gene Therapy 19(11):1065-1074, 20 pages. [cited by applicant]
Zhang, S.-N. et al. (Aug. 2011). “Optimizing DC Vaccination by Combination With Oncolytic Adenovirus Coexpressing IL-12 and GM-CSF,” Molecular Therapy, 19(8):1558-1568. [cited by applicant]
Balar, A.V. et al. (Jul. 2021, e-pub. May 26, 2021). “Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (Keynote-057): An Open-Label, Single-Arm, Multicentre… [cited by applicant]
Boorjian, S.A. et al. (Jan. 2021). “Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Open-Label, Repeat-Dose Clinical Trial,” The Lancet Oncology … [cited by applicant]
Chamie, K. et al. (Nov. 10, 2022). “IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer,” NEJM Evidence 2(1):1-11. [cited by applicant]
clinicaltrials.gov (Jan. 18, 2017). “NCT03022825—QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade … [cited by applicant]
clinicaltrials.gov (Jun. 30, 2020). “NCT04452591—Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus-Calmette-Guerin (BOND-003),” 7 pages. [cited by applicant]
clinicaltrials.gov (May 16, 2016). “NCT02773849—Adstiladrin (=Instiladrin) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC),” 9 pages. [cited by applicant]
Du, T. (2014, e-pub. Jul. 18, 2014). “Tumor-Specific Oncolytic Adenoviruses Expressing Granulocyte Macrophage Colony-Stimulating Factor or Anti-CTLA4 Antibody for the Treatment of Cancers,” Cancer Gene Ther. 21(9):340-3… [cited by applicant]
Non-Final Office Action, mailed Aug. 31, 2022, for U.S. Appl. No. 17/842,406, filed Jun. 16, 2022, 9 pages. [cited by applicant]
Wood, M. et al. (1999). “Biodistribution of an Adenoviral Vector Carrying the Luciferase Reporter Gene Following Intravesical or Intravenous Administration to a Mouse,” Cancer Gene Therapy 6(4):367-372. [cited by applicant]
clinicaltrials.gov (Jun. 26, 2020). NCT04452591—“Study of Cretosimogene Given in Patients with Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus-Calmette-Guerin (BOND-003),” 14 pages. [cited by applicant]